MARKET

SNDX

SNDX

Syndax Pharmaceuticals Inc
NASDAQ
19.94
+0.17
+0.86%
After Hours: 20.00 +0.06 +0.30% 17:36 05/22 EDT
OPEN
19.78
PREV CLOSE
19.77
HIGH
20.55
LOW
19.75
VOLUME
1.15M
TURNOVER
--
52 WEEK HIGH
25.59
52 WEEK LOW
8.59
MARKET CAP
1.77B
P/E (TTM)
-7.1235
1D
5D
1M
3M
1Y
5Y
1D
Syndax Pharmaceuticals Price Target Maintained With a $40.00/Share by HC Wainwright & Co.
Dow Jones · 1d ago
HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $40 Price Target
Benzinga · 1d ago
Analysts Offer Insights on Healthcare Companies: IN8bio (INAB), Syndax Pharmaceuticals (SNDX) and Olema Pharmaceuticals (OLMA)
TipRanks · 1d ago
Syndax To Present Data Showing Favorable Post-Transplant Outcomes With Revumenib In Acute Leukemia And Highlight Ongoing Pivotal Trials At ASCO 2026
Benzinga · 2d ago
Syndax revumenib post-transplant AML maintenance data wins ASCO 2026 oral slot
PUBT · 2d ago
SYNDAX ANNOUNCES FOUR REVUFORJ® (REVUMENIB) ABSTRACTS ACCEPTED FOR ASCO 2026, INCLUDING AN ORAL PRESENTATION OF POST-TRANSPLANT DATA
Reuters · 2d ago
Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data
Barchart · 2d ago
Assessing Syndax Pharmaceuticals (SNDX) Valuation After New Revuforj Leukemia Data Spurs Investor Interest
Simply Wall St · 2d ago
More
About SNDX
Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. It is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. It is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. It is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.

Webull offers Syndax Pharmaceuticals Inc stock information, including NASDAQ: SNDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNDX stock methods without spending real money on the virtual paper trading platform.